INTERVIEW

• Takeda Eager to Build Life Science Hub in Shonan, Offer Research Environment Akin to US East Coast: Exec Hirate
  October 24, 2017

• Me Pharma Sees Opportunities in Low-Cost Strategy, Could Carve Out New Biz Models: President
  August 14, 2017

• Centerpiece of FPMAJ’s Lobbying Push Will Be Price Maintenance Premium: Chairman
  April 14, 2017

• Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO
  April 5, 2017

• Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
  March 6, 2017

• Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
  February 28, 2017

• Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
  February 24, 2017

• CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview
  February 8, 2017

• MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate
  January 16, 2017

• Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
  December 2, 2016

• Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research
  August 18, 2016

• Japan Biosimilar Association Aims to Share Knowledge and Experience to Popularize the Use of Biosimilars: Director General
  August 5, 2016

• Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki
  March 30, 2016

• Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
  March 23, 2015

• EFPIA Japan Chairman Says Drug Costs Won’t Explode
  January 14, 2015

• Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.
  November 28, 2014

ページ

• « 先頭
• ‹ Prev
• 1
• 2